Organon gets Nordic and French rights to commercialize Nilemdo for dyslipidemia
Source: SeekingAlpha
2026-01-08 05:29:40 ET
More on Organon
- Organon: Deep Value With No Clear Catalysts
- Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect
- Insider trades: Boeing, Starbucks, Merck among notable names this week
- Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid U.S. Nexplanon headwinds and Jada divestiture
Read the full article on Seeking Alpha
For further details see:
Organon gets Nordic and French rights to commercialize Nilemdo for dyslipidemia
Organon & Co.
NASDAQ: OGN
OGN Trading
0.08% G/L:
$6.4199 Last:
72,909 Volume:
$6.41 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
